BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 20941526)

  • 1. Topotecan and ifosfamide systemic chemotherapy for CNS involvement of solid tumors.
    Kiewe P; Thiel E; Reinwald M; Korfel A
    J Neurooncol; 2011 Jul; 103(3):629-34. PubMed ID: 20941526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic high-dose methotrexate plus ifosfamide is highly effective for central nervous system (CNS) involvement of lymphoma.
    Fischer L; Korfel A; Kiewe P; Neumann M; Jahnke K; Thiel E
    Ann Hematol; 2009 Feb; 88(2):133-9. PubMed ID: 18679681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel trial of topotecan, ifosfamide, and carboplatin (TIC) in children with recurrent solid tumors.
    Radhakrishnan K; Lee A; Harrison LA; Morris E; Shen V; Gates L; Wells RJ; Wolff JE; Garvin JH; Cairo MS
    Pediatr Blood Cancer; 2015 Feb; 62(2):274-278. PubMed ID: 25382188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study.
    Gonzalez EE; Villanueva N; Fra J; Berros JP; Jimenez P; Luque M; Muñiz I; Blay P; Fernandez Y; Vieitez JM; Muriel C; Sanmamed M; Coto PP; Izquierdo M; Estrada E; Lacave AJ
    Invest New Drugs; 2011 Dec; 29(6):1459-64. PubMed ID: 20464446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study.
    Rujkijyanont P; Photia A; Traivaree C; Monsereenusorn C; Anurathapan U; Seksarn P; Sosothikul D; Techavichit P; Sanpakit K; Phuakpet K; Wiangnon S; Chotsampancharoen T; Chainansamit SO; Kanjanapongkul S; Meekaewkunchorn A; Hongeng S
    BMC Cancer; 2019 Oct; 19(1):961. PubMed ID: 31619207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective trial on topotecan salvage therapy in primary CNS lymphoma.
    Fischer L; Thiel E; Klasen HA; Birkmann J; Jahnke K; Martus P; Korfel A
    Ann Oncol; 2006 Jul; 17(7):1141-5. PubMed ID: 16603598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation.
    Lamond JP; Mehta MP; Boothman DA
    J Neurooncol; 1996 Oct; 30(1):1-6. PubMed ID: 8864997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention.
    Lokiec F
    Ann Oncol; 2006 May; 17 Suppl 4():iv33-6. PubMed ID: 16702183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors.
    Schneider CP; Merkel U; Grübner U; Kath R; Höffken K; Hoffmann A
    J Cancer Res Clin Oncol; 2002 Jun; 128(6):313-8. PubMed ID: 12073049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose finding of ifosfamide administered with a chronic two-week continuous infusion.
    Cartei G; Clocchiatti L; Sacco C; Pella N; Bearz A; Mantero J; Pastorelli D; Salmaso F; Zustovich F
    Oncology; 2003; 65 Suppl 2():31-6. PubMed ID: 14586144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective evaluation of high-dose ifosfamide-related nephrotoxicity in young adult patients with recurrent osteosarcoma previously treated with cisplatin, methotrexate and standard-dose ifosfamide.
    Ferrari S; Zolezzi C; Cesari M; Fasano MC; Lamanna G; Bacci G
    Anticancer Drugs; 1999 Jan; 10(1):25-31. PubMed ID: 10194544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
    Serrone L; Zeuli M; Gamucci T; Nardi M; Cognetti F
    Cancer Chemother Pharmacol; 2001 Mar; 47(3):206-10. PubMed ID: 11320663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ifosfamide and vinorelbine in advanced pretreated ovarian cancer: a phase II study.
    Nardi M; De Marco S; Fabi A; Aloe A; Magnani E; Grandinetti P; Cognetti F
    Cancer Chemother Pharmacol; 2000; 45(6):513-5. PubMed ID: 10854141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of docetaxel and topotecan in patients with solid tumors.
    Tkaczuk KH; Zamboni WC; Tait NS; Meisenberg BR; Doyle LA; Edelman MJ; Hausner PF; Egorin MJ; Van Echo DA
    Cancer Chemother Pharmacol; 2000; 46(6):442-8. PubMed ID: 11138457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraocular lymphoma 2000-2005: results of a retrospective multicentre trial.
    Jahnke K; Korfel A; Komm J; Bechrakis NE; Stein H; Thiel E; Coupland SE
    Graefes Arch Clin Exp Ophthalmol; 2006 Jun; 244(6):663-9. PubMed ID: 16228920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
    Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
    Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
    Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ifosfamide or trofosfamide in patients with intraocular lymphoma.
    Jahnke K; Thiel E; Bechrakis NE; Willerding G; Kraemer DF; Fischer L; Korfel A
    J Neurooncol; 2009 Jun; 93(2):213-7. PubMed ID: 19099202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.